GlobeNewswire Inc | Oct 21, 2021 01:15PM EDT

October 21, 2021

BOSTON, Oct. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday, Oct. 20, by Radius Health, Inc. (NASDAQ: RDUS), please note that the dial-in numbers were listed incorrectly. The correct dial-in numbers are (866) 323-7965 for domestic calls and (346) 406-0961 for international calls. The conference ID remains the same,9322858. The corrected release appears below:

Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a company update.

Conference Call Information:Domestic Dial-In Number: 1 (866) 323-7965International Dial-In Number: 1 (346) 406-0961Conference ID: 9322858Webcast Link: https://edge.media-server.com/mmc/p/945gpbaj

A replay of the conference call will be available onNovember 8at11:30 a.m. ETand a live audio webcast of the call will be archived on the Company's website for ninety days. To access the replay, dial (855) 859-2056 or (404) 537-3406 for International, using conference ID number 9322858. The live audio webcast of the call can be accessed from the Investors section of the Companys website, https://ir.radiuspharm.com/events-and-presentations. The full text of the announcement and financial results will also be available on the Companys website.

About RadiusRadius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Radius lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.

Investor & Media Relations Contact:Ethan HoldawayEmail:investor-relations@radiuspharm.comPhone: (617) 583-2017